Revive Therapeutics Archives

Revive Therapeutics Considers Exploring Bucillamine For Treatment Of Monkeypox

Revive Therapeutics (CSE: RVV) is continuing its efforts into evaluating the uses of Bucillamine, disclosing yesterday an update to its

Revive Therapeutics (CSE: RVV) provided on Tuesday updates regarding the phase 3 clinical trial for oral drug bucillamine as a treatment

Revive Therapeutics (CSE: RVV) announced today that it is expanding its research on oral drug Bucillamine. The firm decided to include

Revive Therapeutics (CSE: RVV) announced today that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (CSE: PHRM).

Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive licensing agreement. The licensing agreement

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its psychedelic assets. The update primarily

Revive Therapeutics (CSE: RVV) this afternoon reported that it is in the process of pursuing a commercialization plan for the

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies.

Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it has entered into a memorandum